Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com - Goldman Sachs maintained its Neutral rating and $47.00 price target on CRISPR Therapeutics (NASDAQ:CRSP), currently trading at $47.46, following additional results from the company’s Phase 1 study of CTX310, an in vivo gene therapy targeting cardiovascular disease. The stock has shown strong momentum, gaining over 21% year-to-date according to InvestingPro data.
The new data from the highest dose level (0.8 mg/kg) demonstrated reductions of up to 82% in triglycerides and 86% in LDL from baseline in high-risk patients, consistent with previously reported efficacy results across active dose levels.
Safety data remained favorable with no clinically significant changes in liver enzymes, no treatment-related severe adverse events, and no grade 3+ adverse events reported, according to Goldman Sachs.
CRISPR Therapeutics has adjusted its timeline for CTX320, its Lp(a)-targeting in vivo gene therapy, with initial data now expected in the first half of 2026 instead of the second quarter of 2025, reflecting what management described as a strategic decision to incorporate insights from the evolving Lp(a) landscape.
The company plans to present the full CTX310 data at a medical meeting in the second half of 2025, which will provide additional information on durability, consistency of benefit, and clinical profile of the treatment. With analyst price targets ranging from $32 to $268, investors can access comprehensive analysis and 12 additional key insights through InvestingPro’s detailed research report.
In other recent news, CRISPR Therapeutics has reported promising data from its Phase 1 clinical trial for the experimental cholesterol drug CTX310, showing significant reductions in triglycerides and LDL cholesterol levels. The data revealed peak reductions of up to 82% in triglycerides and 86% in LDL cholesterol at the highest dose, with a well-tolerated safety profile. The company plans to present complete Phase 1 data for CTX310 at a medical meeting in the latter half of 2025. Additionally, CRISPR Therapeutics announced a delay in the CTX320 program, now expecting data in the first half of 2026 due to strategic decisions in response to the evolving Lp(a) treatment landscape. The company’s preclinical program, CTX340, which targets the AGT gene for refractory hypertension, is progressing toward regulatory filings. Analysts from Brookline Capital Markets maintained a Buy rating on CRISPR Therapeutics, citing the potential of CTX310 to transform cardiovascular disease treatment. William Blair also reiterated an outperform rating, noting competitive LDL-C reduction results. Chardan Capital Markets highlighted Eli Lilly (NYSE:LLY)’s acquisition of Verve Therapeutics as a positive signal for gene-editing therapies, suggesting potential valuation upside for CRISPR Therapeutics in the cardiovascular space.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.